<code id='FBBF442C19'></code><style id='FBBF442C19'></style>
    • <acronym id='FBBF442C19'></acronym>
      <center id='FBBF442C19'><center id='FBBF442C19'><tfoot id='FBBF442C19'></tfoot></center><abbr id='FBBF442C19'><dir id='FBBF442C19'><tfoot id='FBBF442C19'></tfoot><noframes id='FBBF442C19'>

    • <optgroup id='FBBF442C19'><strike id='FBBF442C19'><sup id='FBBF442C19'></sup></strike><code id='FBBF442C19'></code></optgroup>
        1. <b id='FBBF442C19'><label id='FBBF442C19'><select id='FBBF442C19'><dt id='FBBF442C19'><span id='FBBF442C19'></span></dt></select></label></b><u id='FBBF442C19'></u>
          <i id='FBBF442C19'><strike id='FBBF442C19'><tt id='FBBF442C19'><pre id='FBBF442C19'></pre></tt></strike></i>

          Home / Wikipedia / entertainment

          entertainment


          entertainment

          author:comprehensive    Page View:7
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In